Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment
Richard Derman1, Joseph D Kohles2, Ann Babbitt31Department of Obstetrics and Gynecology, Christiana Hospital, Newark, DE, USA; 2Roche, Nutley, NJ, USA; 3Greater Portland Bone and Joint Specialists, Portland, ME, USAAbstract: Data from two open-label trials (PRIOR and CURRENT) of women with postmenop...
Guardado en:
Autores principales: | Richard Derman, Joseph D Kohles, Ann Babbitt |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0de30185bf0e4187965286a0d57c2d8c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Undertreatment of osteoporosis and the role of gastrointestinal events among elderly osteoporotic women with Medicare Part D drug coverage
por: Siris ES, et al.
Publicado: (2015) -
Bisphosphonate use and hip fracture epidemiology: ecologic proof from the contrary
por: Alex Fisher, et al.
Publicado: (2010) -
Strontium ranelate treatment in a postmenopausal woman with osteonecrosis of the jaw after long-term oral bisphosphonate administration: a case report
por: Pan WL, et al.
Publicado: (2017) -
Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis
por: Masashi Uehara, et al.
Publicado: (2021) -
Once-yearly zoledronic acid in hip fracture prevention
por: Oddom Demontiero, et al.
Publicado: (2009)